Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. Fundamental Analysis
Cosmo Pharmaceuticals N.V. (CMOPF) shows moderate financial fundamentals with a PE ratio of 37.14, profit margin of 30.31%, and ROE of 11.53%. The company generates $0.2B in annual revenue with weak year-over-year growth of 1.88%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 81.9/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze CMOPF's fundamental strength across five key dimensions:
Efficiency Score
WeakCMOPF struggles to generate sufficient returns from assets.
Valuation Score
ModerateCMOPF shows balanced valuation metrics.
Growth Score
ModerateCMOPF shows steady but slowing expansion.
Financial Health Score
ExcellentCMOPF maintains a strong and stable balance sheet.
Profitability Score
ModerateCMOPF maintains healthy but balanced margins.
Key Financial Metrics
Is CMOPF Expensive or Cheap?
P/E Ratio
CMOPF trades at 37.14 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, CMOPF's PEG of -0.74 indicates potential undervaluation.
Price to Book
The market values Cosmo Pharmaceuticals N.V. at 4.46 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 27.55 times EBITDA. This signals the market has high growth expectations.
How Well Does CMOPF Make Money?
Net Profit Margin
For every $100 in sales, Cosmo Pharmaceuticals N.V. keeps $30.31 as profit after all expenses.
Operating Margin
Core operations generate 33.20 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $11.53 in profit for every $100 of shareholder equity.
ROA
Cosmo Pharmaceuticals N.V. generates $9.05 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Cosmo Pharmaceuticals N.V. generates strong operating cash flow of $64.20M, reflecting robust business health.
Free Cash Flow
Cosmo Pharmaceuticals N.V. generates strong free cash flow of $57.34M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $3.60 in free cash annually.
FCF Yield
CMOPF converts 2.79% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
37.14
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.74
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.46
vs 25 benchmark
P/S Ratio
Price to sales ratio
11.27
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.006
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.84
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.12
vs 25 benchmark
ROA
Return on assets percentage
0.09
vs 25 benchmark
ROCE
Return on capital employed
0.11
vs 25 benchmark
How CMOPF Stacks Against Its Sector Peers
| Metric | CMOPF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 37.14 | 29.28 | Worse (Expensive) |
| ROE | 11.53% | 820.00% | Weak |
| Net Margin | 30.31% | -19731.00% (disorted) | Strong |
| Debt/Equity | 0.01 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 3.84 | 4.69 | Strong Liquidity |
| ROA | 9.05% | -17993.00% (disorted) | Weak |
CMOPF outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Cosmo Pharmaceuticals N.V.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
281.76%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
586.44%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
870.62%
Industry Style: Defensive, Growth, Innovation
High Growth